M&A Deal Summary

23andMe Acquires Lemonaid Health

On October 22, 2021, 23andMe acquired healthcare services company Lemonaid Health for 400M USD

Acquisition Highlights
  • This is 23andMe’s 1st transaction in the Healthcare Services sector.
  • This is 23andMe’s largest (disclosed) transaction.
  • This is 23andMe’s 1st transaction in the United States.
  • This is 23andMe’s 1st transaction in California.

M&A Deal Summary

Date 2021-10-22
Target Lemonaid Health
Sector Healthcare Services
Buyer(s) 23andMe
Deal Type Add-on Acquisition
Deal Value 400M USD
Advisor(s) Fenwick & West
Nelson Hardiman (Legal)

Target

Lemonaid Health

San Francisco, California, United States
website
Lemonaid Health is an on-demand platform for accessing medical care and pharmacy services online. Lemonaid Health platform leverages clinical algorithms to augment its experienced medical providers’ knowledge base, enabling patients to quickly, safely, and inexpensively get care and prescriptions for a variety of common medical conditions. Lemonaid Health is based in San Francisco, California.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

23andMe

South San Francisco, California, United States

website


Category Company
Founded 2006
Sector Life Science
Revenue 272M USD (2022)
DESCRIPTION

23andMe is a consumer genetics and research company that helps people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple Food and Drug Administration authorizations for genetic health risk reports. 23andMe has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases, conditions, and traits. The platform also powers the 23andMe therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. 23andMe was founded in 2006 and is based in South San Francisco, California.


DEAL STATS #
Overall 1 of 1
Sector (Healthcare Services) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1